LQZ-7F

LQZ-7F, a survivin dimerization inhibitor, induces spontaneous apoptosis and synergizes with Docetaxel in prostate cancer cells. LQZ-7F dose-dependently inhibits survival of both PC-3 and C4-2 cells with IC50s of 2.99 and 2.47 μM, respectively[1].

Product Specifications

CAS Number

[354543-09-2]

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

Apoptosis; Survivin

Type

Reference compound

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/lqz-7f.html

Purity

97.44

Solubility

DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C1=NON=C1N)N/N=C2C3=C(C4=NC5=NON=C5N=C4\2)C=CC=C3

Molecular Formula

C14H7N9O3

Molecular Weight

349.26

Precautions

H315, H319, H320

References & Citations

[1]Robert Peery, et al. A novel survivin dimerization inhibitor without a labile hydrazone linker induces spontaneous apoptosis and synergizes with docetaxel in prostate cancer cells. Bioorg Med Chem. 2022 Jul 1;65:116761.|[2]Qi Jing, et al. Effective Targeting of the Survivin Dimerization Interface with Small-Molecule Inhibitors. Cancer Research. 2016 Jan. 76 (2) :453-462.